) t4 c; r' v3 W1 {% t两个世界排名前十的制药公司正在洽谈寻求一个世界范围内的药品生产许可证,Medipost发言人告诉法新社记者,并补充说一个涉及一大批人的最终试验可能会于2015年在美国开展。 + I+ [5 S4 ?+ m. m3 w3 h6 O7 F: T g* |+ Q- I
(c)2012法新社(生物谷bioon.com) 0 ~; E/ ]1 \* h! ]6 d0 Y% E1 O2 k/ P2 N5 @
S. Korea approves sales of new stem cell drug& \8 q( e2 o8 A! D) o
. Q9 z$ L1 u! j, X" {- B
January 19, 20129 {& h* @+ W/ |6 ]- D
2 @0 ~' \+ R0 W
South Korea's government drug agency cleared the way Thursday for commercial sales of what it called the world's first approved medicine using stem cells collected from other people.* {. i L8 ^6 i9 ]5 u& T2 P
2 j5 U8 I* q7 m. kCartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns' umbilical cord blood, the Korea Food and Drug Administration said.* {! i- r+ T0 s; D8 X0 A
4 g0 ^- V+ c% C! H) q% B! Z, s
"Cartistem is... the world's first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis," the administration said in a statement. / f4 U( q* t* r H8 E) T# r% _; _7 J 5 z& Y# E& H# B" u! L4 Q, HMedipost said 27 billion won ($23.8 million) from private investors andgovernment funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient's knees via surgery. * H4 \, Q, n+ F7 r# G / S. @# v; a8 RClinical trials have been under way in the United States since last year, the statement said. " {9 I+ M4 R4 E' q ( m4 b7 C" a& j, tTwo of the world's top 10 drugmakers are in talks to seek a worldwide licence to make the drug, a Medipost spokesman told AFP, adding that final trials involving a large number of people would likely begin in the US in 2015.8 T5 H$ }$ x$ r0 c
5 r1 d! f e: f$ i) N" W) m% Y
(c) 2012 AFP ( x$ p' k% }9 A9 T d5 t5 K ' Y. v% \" r+ d 5 P8 R) D+ @% A" [. |作者: FreeCell 时间: 2012-1-20 12:45